Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Rizos

Showing results (21-30 of 138) with videos related to

Pageof 14
Sort By:
Cancer|May 26, 2017
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSu Yin Lim, Alexander M Menzies, Helen Rizos
Pigment Cell & Melanoma Research|September 14, 2019
Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitorsZizhen Ming, Su Yin Lim, Richard F Kefford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.
Pigment Cell & Melanoma Research|April 16, 2013
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cellsJason R Todd, Therese M Becker, Richard F Kefford, et al.
Cancer Genetics|December 17, 2018
Evaluation of commercial kits for purification of circulating free DNARussell J Diefenbach, Jenny H Lee, Richard F Kefford, et al.
Critical Reviews in Oncology/Hematology|September 12, 2015
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanomaMatteo S Carlino, Georgina V Long, Richard F Kefford, et al.
Molecular Cancer|March 29, 2025
Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatmentSu Yin Lim, Suzanah C Boyd, Russell J Diefenbach, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2016
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Sarah J Welsh, Helen Rizos, Richard A Scolyer, et al.
Lancet (London, England)|April 19, 2026
Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunitiesWei Yen Chan, Ines Pires da Silva, Georgina V Long, et al.
Oncogenesis|September 22, 2018
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanomaMal Irvine, Ashleigh Stewart, Bernadette Pedersen, et al.
Pageof 14

Showing results (21-30 of 138) with videos related to

Sort By:
Pageof 14
Cancer|May 26, 2017
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSu Yin Lim, Alexander M Menzies, Helen Rizos
Pigment Cell & Melanoma Research|September 14, 2019
Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitorsZizhen Ming, Su Yin Lim, Richard F Kefford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.
Pigment Cell & Melanoma Research|April 16, 2013
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cellsJason R Todd, Therese M Becker, Richard F Kefford, et al.
Cancer Genetics|December 17, 2018
Evaluation of commercial kits for purification of circulating free DNARussell J Diefenbach, Jenny H Lee, Richard F Kefford, et al.
Critical Reviews in Oncology/Hematology|September 12, 2015
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanomaMatteo S Carlino, Georgina V Long, Richard F Kefford, et al.
Molecular Cancer|March 29, 2025
Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatmentSu Yin Lim, Suzanah C Boyd, Russell J Diefenbach, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2016
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Sarah J Welsh, Helen Rizos, Richard A Scolyer, et al.
Lancet (London, England)|April 19, 2026
Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunitiesWei Yen Chan, Ines Pires da Silva, Georgina V Long, et al.
Oncogenesis|September 22, 2018
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanomaMal Irvine, Ashleigh Stewart, Bernadette Pedersen, et al.
Pageof 14